F10 and atrial fibrillation: Despite factor Xa inhibitors being prescribed for atrial fibrillation 20 times more frequently than dabigatran,5 acute care hospitals and trauma centers were 5 times and 3 times less likely, respectively, to have access to andexanet alfa than idarucizumab.